ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements with these filters
Themis Medicare Ltd withdrew its proposed preferential issue of 45,95,795 warrants. The company secured working capital through alternative means, and no adverse impact is expected.
Themis Medicare fixed the record date as September 23, 2026, for its final dividend FY 2025-26, pending AGM approval on September 30, 2026. No dividend per-share amount is stated.
Themis Medicare Limited has issued the notice for its upcoming Annual General Meeting scheduled for September 30, 2026. Shareholders will consider resolutions including dividend declaration.
Themis Medicare Limited has filed its Annual Report for the financial year 2025-26, along with the notice for its 56th Annual General Meeting.
Themis Medicare Limited has clarified to the exchange that there is no pending or delayed material information regarding the recent increase in trading volume.
Themis Medicare has appointed Suresh Savaliya as Company Secretary and Compliance Officer, replacing Nagraj Mogoveera, who transitioned to another role within the company.
Themis Medicare Q1 FY27 revenue hit ₹86.96 Cr with 28.3% PAT margin, significantly boosted by one-off gains of ₹92.95 Cr from share sales.
Themis Medicare Ltd has updated its list of authorized persons responsible for determining the materiality of information and disclosures under SEBI Regulation 30(5).
Themis Medicare Ltd reported revenue from operations of ₹87 Cr (-10.9% YoY) and net profit of ₹24.6 Cr for Q1 FY27.
Themis Medicare Ltd has scheduled a board meeting for August 13, 2026, to approve the standalone and consolidated financial results for the quarter ending June 30, 2026.
Vividhmargi Investments Private Limited, a promoter of Themis Medicare Limited, created a pledge of 30,00,000 equity shares. The pledge represents 3.26% of the company's total share capital.
Themis Medicare Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026. The report includes explanatory notes regarding prior internal promoter group restructuring.
Themis Medicare Ltd filed its quarterly shareholding pattern for the period ended June 2026, noting internal promoter group entity restructuring and shareholding consolidation.
Promoter Vividhmargi Trust created a pledge over 2.53 crore shares of Themis Medicare Ltd as collateral for a ₹135 Crore loan facility.
Vividhmargi Investments Private Limited released a pledge on 15,00,000 equity shares of Themis Medicare. This reduces the promoter group's total encumbered stake to nil.
Pharmaceutical Business Group (India) Limited reported an indirect encumbrance on 47.02% of Gujarat Themis Biosyn's equity. This follows a pledge creation by Vividhmargi Investments.
Vividhmargi Trust pledged 2.53 crore Themis Medicare shares valued at Rs.28.42 Crore. The pledged shares, 27.49% of total, secure a Rs.135 crore loan for personal use.
CTL Trusteeship Ltd disclosed a pledge over 27.49% of Themis Medicare's shares. The pledge, effective June 29, 2026, secures debentures issued by OSS Software Solutions Labs.
Themis Medicare Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report by SAV & Associates LLP confirms adherence to statutory regulations.
Themis Medicare reported Q4 FY26 recovery with ₹76.5cr revenue (up 6.7% YoY) and ₹8.9cr PAT, transitioning from a loss. Strategy focuses on Hospital business growth and API expansion.
Themis Medicare recommended a final dividend of ₹0.5 per equity share for FY 2025-26. Record and meeting dates for shareholder approval will be announced later.
Themis Medicare Ltd reported revenue from operations of ₹76.5 Cr (+6.7% YoY) and net profit of ₹8.9 Cr for Q4 FY26.
Themis Medicare reported audited FY26 financial results and recommended a ₹4.61 Crore final dividend. The board also re-appointed M/s. R. Nanabhoy & Co. as cost auditors.
Themis Medicare scheduled a board meeting for May 28, 2026, to approve FY26 audited financial results. Directors will also consider recommending an equity dividend.
Themis Medicare obtained a Valuation Report and Compliance Certificate for its proposed preferential warrant allotment. These documents support in-principle approval applications filed with stock exchanges.
Themis Medicare Ltd has submitted the RTA compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026. The registrar, MUFG Intime India, confirmed the processing and listing of dematerialised securities within prescribed timelines.